4basebio (4BB) has reported its 1H25 results to 30 June 2025 with revenue growth during the period providing us with a degree of confidence that industry adoption of synthetic DNA is beginning to accelerate. 1H25 revenues of £1.2m were nearly four times higher than 1H24 (1H24: £0.3m) and c25% above the full year 2024 (FY24: £0.9m). 1H25 period end cash was £26.1m (FY24: £34.6m) providing a multi-year runway to support scaling and execution of 4BB’s commercialisation strategy. In our view, the re ....
